“AbbVie is not in discussions with RevMed,” a spokesperson for AbbVie said in a statement to Bloomberg News.
The Wall Street Journal reported Wednesday that AbbVie was in “advanced” talks to purchase Revolution in a deal that could value the company with no products yet on the market at more than $20 billion.
Revolution’s shares fell 12% after markets closed in New York, after surging 32% following the Wall Street Journal report that cited people familiar with the talks. A representative for Revolution declined ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.